The clinical trial titled 'Effect of the Antidiabetic Drug DAPAgliflozin on the Coronary Macrovascular and Microvascular Function in Type 2 Diabetic Patients' was sponsored by the Centre Hospitalier Universitaire Saint Pierre in collaboration with AstraZeneca. The study aimed to assess the cardiovascular benefits of dapagliflozin, an SGLT2 inhibitor, specifically its impact on coronary and microcirculatory function in type 2 diabetes patients. Despite the promising background of SGLT2 inhibitors in reducing cardiovascular events and hospitalizations for heart failure, the trial was terminated due to slow recruitment, which may indicate challenges in patient enrollment for studies focusing on specific cardiovascular outcomes in diabetes. This could reflect on the broader market for SGLT2 inhibitors, suggesting a need for enhanced patient engagement strategies. AstraZeneca's position in the SGLT2 market remains strong, but the termination of this trial may necessitate a reevaluation of ongoing and future studies to ensure robust data generation and market competitiveness.